Introducing Kardia 12L: The first of its kind 12-lead portable ECG | Learn More

AliveCor Logo

Our Products

AFib Screening
Data Integration Solutions
KardiaCare Plus
KardiaComplete
Kardia 12L

New

KardiaMobile 6L
AliveCor K1000
KardiaStation
KardiaPro
Kardia ECG Devices

Our Solutions

Health Systems
Clinical Trials
Patient Engagement
Payors
Employers
OEMs
Veterans Affairs

About

Leadership
Mission
Clinical Research
Our AI
For Consumers
The Human Component Film
Newsroom
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Remote Monitoring Boosts Decentralized Trials

PharmExec.com

An influx in technologies is making it easier for pharma companies to conduct decentralized trials for all therapeutic areas, but designers of these trials need confidence in the technology’s effectiveness.

That’s why, as a RPM manufacturer, AliveCor prioritizes proving the effectiveness. For example, AliveCor received FDA clearance in 2021 for healthcare professionals to use KardiaMobile 6L to collect a crucial piece of information about patients’ heart health: their QTc interval.

For many trials, proven RPM technology showcases that the opportunity to decentralize has arrived.

Key Takeaways:

  • The more companies embrace RPM tools, the faster we’ll normalize decentralized trials
  • Decentralized trials benefit the patient and sponsor
  • The RPM industry is growing rapidly
  • Demonstrating results and undergoing pilot programs is important to RPM manufacturers like AliveCor

Read Full Article

In The News

12 Ways to Improve Adherence

PM360online.com | With treatment plans that require frequent ECG testing, patients with breast cancer are faced with even more challenges. Leveraging KardiaMobile® 6L, an IQVIA program alleviated the pains associated with traditional 12-lead systems.

At-Home Clinical Trials Are the Future

StatNews.com | Hybrid and decentralized clinical trials are rapidly advancing. To ensure DCT success, mobile digital health technologies, like portable ECGs, are proving more necessary than ever.

Remote Monitoring Boosts Decentralized Trials

PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.